<DOC>
	<DOC>NCT00531934</DOC>
	<brief_summary>This 2 arm study will evaluate the management of Tarceva-induced skin rash in patients with non-small cell lung cancer who have failed first-line chemotherapy for advanced disease. Eligible patients will be randomized to receive a)doxycycline 100mg po daily or b)no preventative treatment; all patients will receive Tarceva 150mg/kg po daily. The anticipated time on study treatment is until disease progression or intolerable toxicity, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patients, 1875 years of age; confirmed nonsmall cell lung cancer; failure after first line chemotherapy for advanced disease, and scheduled for second line therapy with Tarceva. rash of any etiology at study entry; history of significant heart disease; any other malignancies (other than adequately treated squamous cell skin cancer, or in situ cancer of the cervix); history of allergic reactions to tetracyclines.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>